Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews
BackgroundNew ways of reimbursement for high-cost, one-shot curative therapies such as advanced therapy medicinal products (ATMPs) are a growing area of interest to stakeholders in market access such as industry representatives, legislative and accounting experts, physicians, hospital managers, hosp...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1397531/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594106188038144 |
|---|---|
| author | Thomas Desmet Thomas Desmet Sissel Michelsen Sissel Michelsen Elena Van den Brande Walter Van Dyck Steven Simoens Isabelle Huys |
| author_facet | Thomas Desmet Thomas Desmet Sissel Michelsen Sissel Michelsen Elena Van den Brande Walter Van Dyck Steven Simoens Isabelle Huys |
| author_sort | Thomas Desmet |
| collection | DOAJ |
| description | BackgroundNew ways of reimbursement for high-cost, one-shot curative therapies such as advanced therapy medicinal products (ATMPs) are a growing area of interest to stakeholders in market access such as industry representatives, legislative and accounting experts, physicians, hospital managers, hospital pharmacists, patient representatives, policymakers, and sickness funds. Due to the complex nature of ATMPs, new payment models and reimbursement modalities are proposed yet not widely applied across Europe.ObjectivesThis study aimed to elicit opinions on and insights into the governance aspect of implementing outcome-based spread payments (OBSP) in Belgium for the reimbursement of innovative therapies. Stakeholders’ responsibilities and roles were analysed and proposed solutions or general beliefs were assessed to identify necessary or sufficient conditions to establish outcome-based spread payments.MethodsSemi-structured interviews (n = 33) were conducted with physicians (n = 2), hospital pharmacists (n = 4), hospital managers (n = 2), Belgian policymakers (n = 6), legislative experts (n = 2), accounting experts (n = 5), representatives of patients (n = 3), of industry (n = 5), and sickness funds (n = 4). The interviews took place between July 2020 and October 2020. The framework method analysis was performed using Nvivo software (version 20.4.1.851). Statements were allocated into six main topics: payment structure, spread payments, outcome-based agreements, governance, transparency, and regulation.ResultsInterviews revealed the necessary conditions that, fulfilled together, are seen to be sufficient for the successful implementation of OBSP, including consensus on pricing, payment logistics, robust data infrastructure and financing, clear agreement terms (duration, outcome parameters, payment triggers), long-term patient follow-up solutions, an external multi-stakeholder governance body, and transparency regarding agreement types.ConclusionDespite the interest, the effective implementation of OBSP falls behind due to a lack of consensus on how this new reimbursement method can be a sustainable solution. By stating the necessary conditions that, when fulfilled together, are deemed sufficient for successful OBSP implementation, this study provides a framework towards overcoming implementation barriers and realizing the potential of OBSP in transforming healthcare reimbursement practices. |
| format | Article |
| id | doaj-art-d98006e4cf164dd08abc31aebc68fc4c |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-d98006e4cf164dd08abc31aebc68fc4c2025-01-20T05:23:47ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.13975311397531Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviewsThomas Desmet0Thomas Desmet1Sissel Michelsen2Sissel Michelsen3Elena Van den Brande4Walter Van Dyck5Steven Simoens6Isabelle Huys7Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumHealthcare Management Centre, Vlerick Business School, Ghent, BelgiumClinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumHealthcare Management Centre, Vlerick Business School, Ghent, BelgiumClinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumHealthcare Management Centre, Vlerick Business School, Ghent, BelgiumClinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumClinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumBackgroundNew ways of reimbursement for high-cost, one-shot curative therapies such as advanced therapy medicinal products (ATMPs) are a growing area of interest to stakeholders in market access such as industry representatives, legislative and accounting experts, physicians, hospital managers, hospital pharmacists, patient representatives, policymakers, and sickness funds. Due to the complex nature of ATMPs, new payment models and reimbursement modalities are proposed yet not widely applied across Europe.ObjectivesThis study aimed to elicit opinions on and insights into the governance aspect of implementing outcome-based spread payments (OBSP) in Belgium for the reimbursement of innovative therapies. Stakeholders’ responsibilities and roles were analysed and proposed solutions or general beliefs were assessed to identify necessary or sufficient conditions to establish outcome-based spread payments.MethodsSemi-structured interviews (n = 33) were conducted with physicians (n = 2), hospital pharmacists (n = 4), hospital managers (n = 2), Belgian policymakers (n = 6), legislative experts (n = 2), accounting experts (n = 5), representatives of patients (n = 3), of industry (n = 5), and sickness funds (n = 4). The interviews took place between July 2020 and October 2020. The framework method analysis was performed using Nvivo software (version 20.4.1.851). Statements were allocated into six main topics: payment structure, spread payments, outcome-based agreements, governance, transparency, and regulation.ResultsInterviews revealed the necessary conditions that, fulfilled together, are seen to be sufficient for the successful implementation of OBSP, including consensus on pricing, payment logistics, robust data infrastructure and financing, clear agreement terms (duration, outcome parameters, payment triggers), long-term patient follow-up solutions, an external multi-stakeholder governance body, and transparency regarding agreement types.ConclusionDespite the interest, the effective implementation of OBSP falls behind due to a lack of consensus on how this new reimbursement method can be a sustainable solution. By stating the necessary conditions that, when fulfilled together, are deemed sufficient for successful OBSP implementation, this study provides a framework towards overcoming implementation barriers and realizing the potential of OBSP in transforming healthcare reimbursement practices.https://www.frontiersin.org/articles/10.3389/fphar.2024.1397531/fullsemi-structured interviewsmanaged entry agreements (MEA)annuityspread paymentoutcome-based reimbursementadvanced therapy medicinal product (ATMP) |
| spellingShingle | Thomas Desmet Thomas Desmet Sissel Michelsen Sissel Michelsen Elena Van den Brande Walter Van Dyck Steven Simoens Isabelle Huys Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews Frontiers in Pharmacology semi-structured interviews managed entry agreements (MEA) annuity spread payment outcome-based reimbursement advanced therapy medicinal product (ATMP) |
| title | Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews |
| title_full | Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews |
| title_fullStr | Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews |
| title_full_unstemmed | Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews |
| title_short | Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews |
| title_sort | towards implementing new payment models for the reimbursement of high cost curative therapies in europe insights from semi structured interviews |
| topic | semi-structured interviews managed entry agreements (MEA) annuity spread payment outcome-based reimbursement advanced therapy medicinal product (ATMP) |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1397531/full |
| work_keys_str_mv | AT thomasdesmet towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT thomasdesmet towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT sisselmichelsen towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT sisselmichelsen towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT elenavandenbrande towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT waltervandyck towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT stevensimoens towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews AT isabellehuys towardsimplementingnewpaymentmodelsforthereimbursementofhighcostcurativetherapiesineuropeinsightsfromsemistructuredinterviews |